AGNPF
Price
$0.05
Change
-$0.01 (-16.67%)
Updated
Jul 2 closing price
Capitalization
1.3M
WVE
Price
$6.95
Change
+$0.20 (+2.96%)
Updated
Jul 3 closing price
Capitalization
1.08B
25 days until earnings call
Interact to see
Advertisement

AGNPF vs WVE

Header iconAGNPF vs WVE Comparison
Open Charts AGNPF vs WVEBanner chart's image
Algernon Pharmaceuticals
Price$0.05
Change-$0.01 (-16.67%)
Volume$66.71K
Capitalization1.3M
Wave Life Sciences
Price$6.95
Change+$0.20 (+2.96%)
Volume$652.46K
Capitalization1.08B
AGNPF vs WVE Comparison Chart in %
Loading...
AGNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGNPF vs. WVE commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGNPF is a Hold and WVE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (AGNPF: $0.05 vs. WVE: $6.95)
Brand notoriety: AGNPF and WVE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGNPF: 247% vs. WVE: 50%
Market capitalization -- AGNPF: $1.3M vs. WVE: $1.08B
AGNPF [@Biotechnology] is valued at $1.3M. WVE’s [@Biotechnology] market capitalization is $1.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGNPF’s FA Score shows that 2 FA rating(s) are green whileWVE’s FA Score has 0 green FA rating(s).

  • AGNPF’s FA Score: 2 green, 3 red.
  • WVE’s FA Score: 0 green, 5 red.
According to our system of comparison, AGNPF is a better buy in the long-term than WVE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGNPF’s TA Score shows that 1 TA indicator(s) are bullish while WVE’s TA Score has 5 bullish TA indicator(s).

  • AGNPF’s TA Score: 1 bullish, 5 bearish.
  • WVE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, WVE is a better buy in the short-term than AGNPF.

Price Growth

AGNPF (@Biotechnology) experienced а -14.85% price change this week, while WVE (@Biotechnology) price change was -1.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

WVE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WVE($1.08B) has a higher market cap than AGNPF($1.3M). AGNPF YTD gains are higher at: 4.827 vs. WVE (-43.816). AGNPF has higher annual earnings (EBITDA): -1.62M vs. WVE (-117.1M). WVE has more cash in the bank: 243M vs. AGNPF (92.2K). WVE has higher revenues than AGNPF: WVE (105M) vs AGNPF (0).
AGNPFWVEAGNPF / WVE
Capitalization1.3M1.08B0%
EBITDA-1.62M-117.1M1%
Gain YTD4.827-43.816-11%
P/E Ratio2.21N/A-
Revenue0105M-
Total Cash92.2K243M0%
Total DebtN/A23.6M-
FUNDAMENTALS RATINGS
AGNPF vs WVE: Fundamental Ratings
AGNPF
WVE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3398
PRICE GROWTH RATING
1..100
8456
P/E GROWTH RATING
1..100
80100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGNPF's Valuation (27) in the null industry is in the same range as WVE (54) in the Biotechnology industry. This means that AGNPF’s stock grew similarly to WVE’s over the last 12 months.

AGNPF's Profit vs Risk Rating (100) in the null industry is in the same range as WVE (100) in the Biotechnology industry. This means that AGNPF’s stock grew similarly to WVE’s over the last 12 months.

AGNPF's SMR Rating (33) in the null industry is somewhat better than the same rating for WVE (98) in the Biotechnology industry. This means that AGNPF’s stock grew somewhat faster than WVE’s over the last 12 months.

WVE's Price Growth Rating (56) in the Biotechnology industry is in the same range as AGNPF (84) in the null industry. This means that WVE’s stock grew similarly to AGNPF’s over the last 12 months.

AGNPF's P/E Growth Rating (80) in the null industry is in the same range as WVE (100) in the Biotechnology industry. This means that AGNPF’s stock grew similarly to WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGNPFWVE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AGNPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IHSSX25.390.30
+1.20%
Hartford Small Company R4
FTMSX26.090.24
+0.93%
FullerThaler Behvrl Mcr-Cp Eq Instl
FLCCX45.780.38
+0.84%
Fidelity Advisor Large Cap C
SCCUX11.320.06
+0.53%
Invesco Income Advantage U.S. Fund C
AMVYX16.230.04
+0.25%
American Century Mid Cap Value Y

AGNPF and

Correlation & Price change

A.I.dvisor tells us that AGNPF and CYDY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AGNPF and CYDY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGNPF
1D Price
Change %
AGNPF100%
N/A
CYDY - AGNPF
24%
Poorly correlated
+5.56%
WVE - AGNPF
23%
Poorly correlated
+2.96%
PHIO - AGNPF
21%
Poorly correlated
-3.23%
IBIO - AGNPF
20%
Poorly correlated
+0.14%
ABCZF - AGNPF
12%
Poorly correlated
N/A
More